| Jongen PJ, Sindic C, Carton H, et al.
Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after 2 years of treatment with intramuscular interferon-beta-1a. [JOURNAL ARTICLE]
J Neurol 2009 Nov 18.
Abstract | Full Citation | | Radziwill AJ, Botez SA, Novy J, et al.
Interferon beta-1a as adjunctive treatment for multifocal motor neuropathy: an open label trial. [Letter]
J Peripher Nerv Syst 2009 Sep; 14(3):201-2.
Full Citation | Find Related Articles | | Aristimuño C, de Andrés C, Bartolomé M, et al.
IFNbeta-1a therapy for multiple sclerosis expands regulatory CD8(+) T cells and decreases memory CD8(+) subset: A longitudinal 1-year study. [JOURNAL ARTICLE]
Clin Immunol 2009 Nov 8.
Abstract | Full Citation | | Chen YM, Yang CC, Wang IH, et al.
The effect of interferon beta-1a on optic neuritis relapse in patients with multiple sclerosis. [JOURNAL ARTICLE]
Graefes Arch Clin Exp Ophthalmol 2009 Oct 6.
Abstract | Full Citation | Find Related Articles | | Post JW, Colleaux K
Interferon beta retinopathy in a patient with multiple sclerosis. [Letter]
Can J Ophthalmol 2009 Oct; 44(5):e37.
Full Citation | Find Related Articles | | Salvatore E, Morra VB, Orefice G, et al.
Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. [Comment, Letter]
Neurology 2009 Sep 29; 73(13):1078; author reply 1078-9.
Full Citation | Publisher Full Text | Find Related Articles | | Ramgolam VS, Sha Y, Jin J, et al.
IFN-beta inhibits human Th17 cell differentiation. [Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't]
J Immunol 2009 Oct 15; 183(8):5418-27.
Abstract | Full Citation | Find Related Articles | | Vandenbark AA, Huan J, Agotsch M, et al.
Interferon-beta-1a treatment increases CD56(bright) natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis. [JOURNAL ARTICLE]
J Neuroimmunol 2009 Sep 14.
Abstract | Full Citation | Find Related Articles | | Goldberg LD, Edwards NC, Fincher C, et al.
Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. [Journal Article]
J Manag Care Pharm 2009 Sep; 15(7):543-55.
Abstract | Full Citation | Find Related Articles | | Simó M
[Therapy of multiple sclerosis] [English Abstract, Journal Article]
Neuropsychopharmacol Hung 2009 Mar; 11(1):23-6.
Abstract | Full Citation | Find Related Articles |   |
|
| | Enter
www.unboundmedicine.com/medline
in your iPhone browser
or View our
Unbound MEDLINE
iPhone demo
Advertise on this site.
|
